[Edaily Reporter Kwon Oh Seok ] Shares of #PROTEINA CO., LTD., a protein-protein interaction (PPI)-based artificial intelligence (AI) drug discovery company, are showing strength in early trading. Buying interest appears to be surging following news that the company has entered into a collaboration with a global pharmaceutical firm.

According to MP Doctor on the 22nd, as of 9:20 a.m., PROTEINA CO., LTD.’s stock is trading at 33,500 won, up 6.18% from the previous trading day.
Earlier today, PROTEINA CO., LTD. issued a press release stating, “We have signed a contract for protein-protein interaction biomarker analysis services with a U.S. multinational pharmaceutical company developing treatments for degenerative brain diseases.” However, the name of the pharmaceutical company was not disclosed in accordance with the terms of the contract.
This contract marks the company’s first global commercial agreement, following on the heels of a research collaboration signed last November with the Michael J. Fox Foundation (MJFF), a U.S.-based Parkinson’s disease research foundation. Industry observers note that the network established with the MJFF served as a stepping stone leading to this collaboration with a multinational pharmaceutical company.
PROTEINA CO., LTD. explained that its proprietary PPI-based biomarker technology enables the selective and precise measurement of trace amounts of activated protein complexes. The company noted that this technology differentiates itself from existing methods by analyzing functional changes—such as protein-protein interactions and actions—rather than simply measuring protein concentration.
Under the agreement, the pharmaceutical company plans to use PROTEINA CO., LTD.’s biomarker during the preclinical phase of its brain disease candidate to verify its ability to suppress neuroinflammation and incorporate these findings into the design of subsequent clinical trials.